Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Buy” by Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNMGet Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $29.80.

Several research firms have recently issued reports on IMNM. JPMorgan Chase & Co. began coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Guggenheim initiated coverage on shares of Immunome in a report on Monday, April 15th. They set a “buy” rating and a $35.00 price objective for the company. Piper Sandler initiated coverage on shares of Immunome in a report on Friday. They set an “overweight” rating and a $27.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Tuesday, May 14th.

Get Our Latest Stock Report on Immunome

Insider Buying and Selling at Immunome

In other Immunome news, Director Jean Jacques Bienaime bought 2,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were acquired at an average price of $13.57 per share, with a total value of $27,140.00. Following the transaction, the director now owns 9,615 shares of the company’s stock, valued at approximately $130,475.55. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. EntryPoint Capital LLC grew its position in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after buying an additional 5,466 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Immunome in the 4th quarter worth approximately $172,000. Sei Investments Co. purchased a new position in shares of Immunome in the 1st quarter worth approximately $469,000. Clear Creek Financial Management LLC purchased a new position in shares of Immunome in the 1st quarter worth approximately $547,000. Finally, California State Teachers Retirement System purchased a new position in shares of Immunome in the 1st quarter worth approximately $807,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Down 2.3 %

IMNM stock opened at $14.59 on Tuesday. The company has a fifty day simple moving average of $17.00 and a two-hundred day simple moving average of $16.32. The firm has a market capitalization of $874.95 million, a P/E ratio of -1.93 and a beta of 1.87. Immunome has a 52 week low of $4.50 and a 52 week high of $30.96.

Immunome (NASDAQ:IMNMGet Free Report) last released its earnings results on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $3.40 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. As a group, analysts anticipate that Immunome will post -1.4 EPS for the current year.

About Immunome

(Get Free Report

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Featured Articles

Analyst Recommendations for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.